Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]), the Cambridge, MA-based developer of RNA-interference drugs, said today it has set a goal of moving five RNAi development programs into advanced clinical testing by 2015. Alnylam also named a new drug candidate for refractory anemia, which it hopes to move into clinical trials in 2012. The company said it hopes to form new partnerships, and that it expects to finish this year with more than $275 million of cash and investments left in the bank—meaning that it expects to reach its goals while burning less than $70 million of its existing cash reserves.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
